MMRGlobal CEO Briefs Congressional Oversight Subcommittee on Questions Surrounding Better Ways to Have Spent $11 Billion on HIT Incentives

LOS ANGELES, CA--(Marketwire - Feb 22, 2013) - Robert H. Lorsch, Chairman and CEO of MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, recently met with U.S. Congressional Representatives along with their staffs and the staff of the Subcommittee on Oversight of the House Committee on Science, Space, and Technology. The purpose of the meeting was to brief Representatives and staff on an independent compilation of articles, blogs, reports and opinions pertaining to questions surrounding the payments of nearly $11 billion in stimulus monies under the government's EHR and Meaningful Use incentive programs. The meeting was also intended to address concerns that primary requirements set forth in federal legislation pertaining to the provisioning of Electronic Health Records (EHRs) were not being met, specifically those which pertain to standardization, interoperability and requirements that most Americans have access to all their protected personal health information through some type of secure Personal Health Record similar to existing offerings from MMR.

According to Lorsch, "After the briefing portion of my presentation, I was able to demonstrate to staff the MyMedicalRecords Personal Health Record and explain how it could be deployed to everyone in America at an annual cost that would be less than the cost of one EMR system in a large hospital. At that time, I had no idea that the points raised in my presentation would become Page One of The New York Times the following Wednesday, less than one week later." (http://www.nytimes.com/2013/02/20/business/a-digital-shift-on-health-data-swells-profits.html?_r=0)

While in Washington, Lorsch was also asked to attend a meeting with Representative Dana Rohrabacher regarding the plight of Dr. Shakil Afridi, the Pakistani physician who verified Osama bin Laden's location for the United States. Today, Dr. Afridi is in a Pakistan prison sentenced to 33 years, abandoned, and reportedly being tortured. As a result of that meeting, Lorsch began a campaign which launched in a Special Oscars® issue of The Hollywood Reporter today, and at www.FreeAfridi.com. The campaign appeals for the release of Dr. Afridi by asking that the celebrities attending the Oscars® share a moment of their limelight to help draw attention to America's abandoned hero. (http://losangeles.cbslocal.com/2013/02/20/can-zero-dark-thirty-oscars-help-free-imprisoned-doctor-who-helped-find-bin-laden) 

"After making numerous presentations on behalf of MyMedicalRecords, where I requested support for PHRs, this was the first time that I left Washington believing that the value of a cost-effective, patient-controlled Personal Health Record was being embraced. That includes previous meetings and presentations to former HHS Secretary Mike Leavitt and Homeland Security Secretary Tom Ridge, Congressional Representatives including senior staff members in the office of The Honorable Ted Kennedy, as well as ONC staff and former National Coordinators for Health IT, David J. Brailer, M.D. and David Blumenthal, M.D.," Lorsch added.

The briefing also emphasized the point that without standardization, the current HIT infrastructure did not allow a level playing field for small businesses competing with larger health IT equipment and system providers who dominate more than two-thirds of the marketplace. Information included in the briefing also covered how contractual terms from larger EMR systems are written to discourage hospitals from using other vendors which is counter to requirements of standardization and interoperability.

MMR's technology specifically addresses the issues of interoperability while provisioning a comprehensive Personal Health Record to the patient. The Company offers solutions for patients, physicians and hospitals that seamlessly connect along the lines of the government's stated goal of interoperability and empowering patients, providing access to their health information in a PHR. MMRGlobal also has an extensive healthcare IT patent portfolio, which includes seven U.S. patents: Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240. The MMR Patent Portfolio includes nearly 400 claims as well as additional applications and continuation applications. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. MMR also has been granted patents and has other pending applications in countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South Korea, Israel, and European nations.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, sources, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.